April 13, 2026 — Laekna (2105.HK) released its 2025 Environmental, Social and Governance (ESG) report yesterday.  

“Over the past three years, with the strong support of our employees, investors, partners, experts, and stakeholders, our ESG efforts have achieved ’progressive acceleration’: continuously gaining momentum and building up steadily through accumulated efforts.” said Dr. Chris Lu, Chairman & CEO of Laekna. He stated: 

• - As a science-driven biopharmaceutical company, our innovative internal discovery research is in a phase of “progressive acceleration”
• - In terms of new drug accessibility, our pivotal clinical studies are experiencing "progressive acceleration"
• - In the realm of corporate social responsibility, our public welfare initiatives are also in "progressive acceleration"

Dr. Chris Lu emphasized that “If drug development is a marathon, then ESG building is just the same. We look forward to continuously pushing the boundaries of innovative medicine, enhancing drug accessibility, creating economic and social value, while maintaining sustainable and compliant operations.

2025 ESG Performance Highlights

Robust Quality System Safeguards 

To advance the commercialization process of our products, Laekna has fully adhered to the Market Authorisation Holder (MAH) system and streamlined our internal processes accordingly:

• - Comprehensively upgraded our digitalized Quality Management System (QMS) to strengthen drug quality and compliance management. The system is compliant with US 21 CFR Part 11 regulations
• - Enabled digitalized monitoring across the entire workflow from R&D to production, replacing paper records with real-time electronic data

Building Green Supply Chain 

Effective from 1 January 2025, Laekna has formally integrated environmental and social performance evaluation into its vendor selection procedures for critical suppliers. Our evaluation for key suppliers encompasses, but is not limited to, pollution control, carbon emission intensity, resource efficiency, fair employment practices, occupational health and safety, and research ethics:

• - For engagements involving drug development or regulatory requirements, we conducted enhanced due diligence. This ensures absolute alignment with Good Practice (GxP) guidelines and our internal quality standards
• - Purchases from new suppliers whose ESG performance was assessed accounted for 53% of total procurement spending in 2025

Empower Employee Development with Core Values 

Accountability, Collaboration, Excellence, Integrity, Open, and Resilience —these core values are the corner stone of employee growth and development. They guide us to listen to our people, progressing toward a sustainable future for both the people and the company.

• - Fostered an open and co-created learning ecosystem - "Lai Learning" workshop series invited employees to become the designers and facilitators of training sessions, pursue continuous learning in AI and other emerging technologies, and reinforce our shared commitment to compliance.
• - Actively supported female employees in leveraging their expertise and influence across functions such as novel drug R&D and operations

Mapping Our Green Commuting Footprint 

First time to launch a comprehensive employee commuting survey in 2025:

• - Collected essential data for our Scope 3 emissions accounting
• - Through the survey process, we actively introduced and promoted the concept of green commuting, encouraging sustainable travel choices and raising company-wide awareness on reducing our collective environmental footprint

The survey results revealed that over 70% of our employees have adopted low-carbon commuting practices, covering modes such as walking, bicycling, public transportation, and electric vehicles.

Driving CSR through Innovation

Laekna focuses on innovative and sustainable public welfare initiatives, constantly strengthening and growing our CSR commitment. 

• - Continue to deepen the public welfare initiative “Laekna Children’s Science Innovation Classroom” in Gansu Province. Scientists from Laekna answered questions from children of western regions via video to spark their interest in science
• - Joined the charitable community of "Huai Ai ∞ Circular Charity Shop" of Huaihai Middle Road in Shanghai's Huangpu District
• - Nearly 20 employees completed the American Heart Association (AHA) "Heartsaver" First Aid Training and received their certificates

–  End –

Contact Us

IR  ir@laekna.com

Corporate and Business Development  BD@laekna.com

About Laekna

HKEK Stock Code: 2105.HK

Patient needs in major disease areas—such as metabolic diseases, oncology, and liver fibrosis—remain the driving force behind our mission. Laekna, a science-driven biotechnology company, is committed to bringing novel therapeutics to patients around the world.

Leveraging our tremendous experience and extensive know-how in disease biology, we have built a pipeline of over 20 internally discovered innovative drug candidates with proprietary intellectual property rights. We keep expanding our global reach through strategic partnerships, fostering collaborative success across regions.

In oncology, we have completed subject enrollment for the Phase III clinical trial of LAE002 (afuresertib, an AKT inhibitor) for breast cancer (AFFIRM-205). We plan to submit NDA to the CDE in 2026, which will mark Laekna’s pivotal transition from clinical development to commercialization. Laekna has entered into an exclusive licensing agreement with Qilu Pharma to further accelerate the delivery of this novel therapeutic to patients across China.

In metabolic diseases, building on our deep expertise and extensive knowhow in the ActRII pathway, we have established a globally competitive, differentiated portfolio comprising LAE102, LAE103, and LAE123. We are rapidly advancing the clinical development of LAE102 in both China and the United States. In the U.S., Laekna has successfully completed the Phase I SAD study, in collaboration with Eli Lilly, to accelerate the global development of this high-quality weight management therapy.

From our laboratory in Zhangjiang Pharma Valley in Shanghai, to clinical trials conducted across China, the U.S., and Australia, our footprint spans the globe. Looking ahead, Laekna will continue to collaborate with international partners to accelerate delivery of novel therapeutics to patients worldwide.

For more information, please visit: https://www.laekna.com/  or https://www.linkedin.com/company/74110713/

Forward-Looking Statements

This press release may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on Laekna’s current beliefs, assumptions and expectations, commonly identified by words such as "would", "may", "expects", "believes", "plans", "intends", "projects" and other terms with similar meaning. Although we believe that our predictions are reasonable, future events are inherently uncertain and our actual future results or performance may be materially different from what we expect. Accordingly, you are strongly cautioned that reliance on any forward-looking statements is subject to significant known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.